These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Lorazepam reduces cardiac vagal modulation in normal subjects. Vogel LR; Muskin PR; Collins ED; Sloan RP J Clin Psychopharmacol; 1996 Dec; 16(6):449-53. PubMed ID: 8959471 [TBL] [Abstract][Full Text] [Related]
48. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Ellinwood EH; Heatherly DG; Nikaido AM; Bjornsson TD; Kilts C Psychopharmacology (Berl); 1985; 86(4):392-9. PubMed ID: 2863843 [TBL] [Abstract][Full Text] [Related]
49. Clinical aspects of chronic use of alprazolam and lorazepam. Romach M; Busto U; Somer G; Kaplan HL; Sellers E Am J Psychiatry; 1995 Aug; 152(8):1161-7. PubMed ID: 7625464 [TBL] [Abstract][Full Text] [Related]
50. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. O'Neill WM; Hanks GW; Simpson P; Fallon MT; Jenkins E; Wesnes K Pain; 2000 Mar; 85(1-2):209-15. PubMed ID: 10692620 [TBL] [Abstract][Full Text] [Related]
51. Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Aranko K; Mattila MJ; Seppälä T Br J Clin Pharmacol; 1983 May; 15(5):545-52. PubMed ID: 6134543 [TBL] [Abstract][Full Text] [Related]
52. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers. Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926 [TBL] [Abstract][Full Text] [Related]
53. Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Semlitsch HV; Anderer P; Saletu B Eur J Clin Pharmacol; 1995; 49(3):183-91. PubMed ID: 8665994 [TBL] [Abstract][Full Text] [Related]
54. [Double-blind controlled trial comparing alprazolam and lorazepam in ambulatory anxious patients]. Hecquet S; Puech AJ; Lecrubier Y Therapie; 1984; 39(3):253-61. PubMed ID: 6147031 [No Abstract] [Full Text] [Related]
55. Effects of lorazepam on the neuromagnetic mismatch negativity (MMNm) and auditory evoked field component N100m. Rosburg T; Marinou V; Haueisen J; Smesny S; Sauer H Neuropsychopharmacology; 2004 Sep; 29(9):1723-33. PubMed ID: 15127083 [TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry. Saletu B; Grünberger J; Linzmayer L; Semlitsch HV; Anderer P; Chwatal K Br J Clin Pharmacol; 1994 Feb; 37(2):145-56. PubMed ID: 7910470 [TBL] [Abstract][Full Text] [Related]
57. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. Evans SM; Troisi JR; Griffiths RR J Pharmacol Exp Ther; 1994 Nov; 271(2):683-94. PubMed ID: 7965783 [TBL] [Abstract][Full Text] [Related]
58. Effects of lorazepam on cardiac vagal tone during rest and mental stress: assessment by means of spectral analysis. Tulen JH; Mulder G; Pepplinkhuizen L; Man in 't Veld AJ; van Steenis HG; Moleman P Psychopharmacology (Berl); 1994 Feb; 114(1):81-9. PubMed ID: 7846210 [TBL] [Abstract][Full Text] [Related]
59. Selectivity in the generalization profile in baboons trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative/anxiolytics. Ator NA; Griffiths RR J Pharmacol Exp Ther; 1997 Sep; 282(3):1442-57. PubMed ID: 9316858 [TBL] [Abstract][Full Text] [Related]
60. [Behavioral and electroencephalographic effects of alprazolam and its metabolites (author's transl)]. Ueki S; Watanabe S; Yamamoto T; Kataoka Y; Tazoe N; Shibata S; Shibata K; Ohta H; Kawahara K; Takano M; Suwandi D; Lee SC; Liou SY Nihon Yakurigaku Zasshi; 1981 May; 77(5):483-509. PubMed ID: 7197658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]